Gain Therapeutics Announces Positive Phase 1 Results For GT-02287 In GBA1 Parkinson's Disease Trial

19h ago, source:

Gain Therapeutics, Inc. (GANX) announced positive findings from the single ascending dose segment of the Phase 1 clinical ...

Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)

14d ago, source: Zacks.com on MSN

A downtrend has been apparent in Gain Therapeutics, Inc. (GANX) lately with too much selling pressure. The stock has declined 25.9% over the past four weeks. However, given the fact that it is now in ...

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

23d ago, source: Nasdaq

BETHESDA, Md., April 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company ...

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

1mon ago, source: Business Insider

BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company ...

Gain Therapeutics Inc GANX

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

29d ago, source: Stockhouse

About Gain Therapeutics, Inc. Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s ...

Gain Therapeutics Inc.

28d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

23d ago, source: Stockhouse

BETHESDA, Md., April 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company ...

Gain Therapeutics Inc GANX

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

1mon ago, source: WDRB

Gain Therapeutics, Inc. Consolidated Statement of Operations Year Ended December 31, 2023 2022 Revenues: Collaboration revenues $ 55,180 $ 132,640 Other income ...

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

24d ago, source: ADVFN

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation allosteric small ...

Gain Therapeutics Inc (GANX)

11d ago, source: Investing

Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock ...